Want to see RAPP full AI Analyst Report?
Rapport Therapeutics, Inc. (RAPP) Ratios
Rapport Therapeutics, Inc. Ratios
RAPP's free cash flow for Q2 2026 was $-41.53M. For the 2026 fiscal year, RAPP's free cash flow was decreased by $-78.00K and operating cash flow was $-41.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 26.17 | 35.34 | 17.14 | 18.80 |
| Quick Ratio | 26.17 | 35.34 | 17.14 | 18.80 |
| Cash Ratio | 2.76 | 6.48 | 7.97 | 18.74 |
| Solvency Ratio | -3.98 | -8.15 | -0.19 | -0.88 |
| Operating Cash Flow Ratio | -4.59 | -7.39 | -3.09 | -1.95 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 470.78M | $ 300.30M | $ -30.18M | $ 19.17M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.02 | 0.00 | 0.01 | 0.33 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | -0.08 | 0.53 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | -0.09 | 0.35 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.35 |
| Financial Leverage Ratio | 1.06 | 1.03 | -6.06 | 1.62 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -36.32 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -36.38 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.24 | 0.07 | 0.01 | 0.05 |
| Net Debt to EBITDA | 0.33 | 0.71 | 1.96 | 2.00 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.03% | 100.00% |
| EBT Per EBIT | 89.12% | 94.28% | 96.12% | 102.75% |
| Return on Assets (ROA) | -21.76% | -24.86% | -22.38% | -33.71% |
| Return on Equity (ROE) | -23.00% | -25.64% | 135.70% | -54.61% |
| Return on Capital Employed (ROCE) | -25.36% | -27.13% | -24.68% | -34.63% |
| Return on Invested Capital (ROIC) | -25.21% | -27.06% | -24.56% | -34.63% |
| Return on Tangible Assets | -21.76% | -24.86% | -22.38% | -33.71% |
| Earnings Yield | -7.82% | -21.28% | -0.93% | -0.25% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.43 | 0.04 | 0.01 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -850.07 | -8153.84 | -35283.33 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 850.07 | 8153.84 | 35283.33 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -1.86 | -3.13 | -0.15 | -0.02 |
| Free Cash Flow Per Share | -1.88 | -3.24 | -0.16 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | -142.00 | -26.96 | -16.61 | -11.42 |
| Capital Expenditure Coverage Ratio | -142.00 | -26.96 | -16.61 | -11.42 |
| Operating Cash Flow Coverage Ratio | -7.62 | -43.92 | -12.67 | -0.31 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -6.18% | -18.27% | -0.77% | -0.08% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -10.61 | -4.69 | -108.10 | -392.82 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.94 | 1.20 | -146.70 | 214.53 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -16.18 | -5.47 | -130.49 | -1186.71 |
| Price-to-Operating Cash Flow Ratio | -16.29 | -5.67 | -138.35 | -1290.67 |
| Price-to-Earnings Growth (PEG) Ratio | 0.44 | -0.02 | -0.42 | 0.00 |
| Enterprise Value Multiple | -11.16 | -4.03 | -106.52 | -402.20 |
| Enterprise Value | 1.38B | 312.57M | 3.69B | 4.16B |
| EV to EBITDA | -11.16 | -4.03 | -106.52 | -402.20 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -15.71 | -4.65 | -128.13 | -1180.83 |
| EV to Operating Cash Flow | -15.82 | -4.82 | -135.84 | -1284.28 |
| Tangible Book Value Per Share | 10.32 | 14.73 | -0.14 | 0.10 |
| Shareholders’ Equity Per Share | 10.32 | 14.73 | -0.14 | 0.10 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.37 | -3.78 | -0.19 | -0.05 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.89 | 1.00 | 1.00 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.78 | 0.83 | 0.78 | 0.30 |
Currency in USD
